ARS Pharmaceuticals Doubles Epinephrine Market Share as neffy Revenue Climbs
SPRY is trading near its 52-week low of $4.91 (8.1% above the low).
Summary
ARS Pharmaceuticals reported Q2 results showing neffy net product revenue rose and U.S. epinephrine market share doubled year-over-year, driven by a shift to targeted provider engagement and a completed sales force expansion. The company posted a Q2 net loss of $62.3 million on operating expenses of $95.1 million, reflecting heavy media and sales investment. Management guided 2H 2026 SG&A and R&D expenses to $114-126 million and expects cash flow breakeven by end of 2027. Interim Phase 2b data for the CSU program is expected in Q1 2027. This follows a turbulent period: shares plunged 23% in June after neffy failed to secure new commercial coverage, and the company replaced its CEO and lost its chairman and CMO in July. The market share doubling and prescriber base growth to over 16,000 suggest the commercial strategy is gaining traction despite the earlier setback.
At the time of this announcement, SPRY was trading at $5.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $605.7M. The 52-week trading range was $4.91 to $16.65. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.